Ethical and Regulatory Foundations of Clinical Research
Clinical research rests on a layered rulebook, and exam questions love the seams between the layers. Know the lineage: Nuremberg Code → Declaration of Helsinki → Belmont Report (respect for persons, beneficence, justice) → ICH E6 Good Clinical Practice → national law. In the United States, the operative rules are 21 CFR Part 50 (human subject protection and informed consent), Part 56 (IRBs), Part 312 (IND drugs/biologics), Part 812 (devices), plus HIPAA authorisation for use of protected health information.
Informed consent
Under 21 CFR 50.25, consent must contain the eight basic elements (purpose, procedures, risks, benefits, alternatives, confidentiality, compensation/medical treatment for injury, contacts) plus the additional statements, be in language the subject understands, avoid exculpatory language and waiver of rights, and be documented before any study-specific procedure. The subject (or legally authorised representative) signs and dates first; the person conducting the discussion then signs and dates. Minors require parental permission plus, where appropriate, assent.
IRB/IEC
At least five members, at least one non-scientific and one unaffiliated with the institution, quorum must include a non-scientific member, conflicted members recuse, and continuing review occurs at intervals appropriate to risk but not less than annually.
Traps
- Signing consent after a study-required washout or washout-driven screening test.
- Confusing assent with permission (assent never replaces parental permission).
- Assuming IRB approval means FDA approval, or that a protocol deviation is always a violation.
- Therapeutic misconception: believing the consent discussion may promise benefit.
Rule of thumb: if you cannot point to the regulation or GCP clause that permits an action, treat it as prohibited until the sponsor and IRB confirm in writing.